- Previous Close
10.52 - Open
10.70 - Bid --
- Ask --
- Day's Range
10.60 - 10.76 - 52 Week Range
7.89 - 17.04 - Volume
2,449 - Avg. Volume
19,981 - Market Cap (intraday)
661.894M - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.43 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.80
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
www.abivax.comRecent News: ABVX.PA
View MorePerformance Overview: ABVX.PA
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABVX.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABVX.PA
View MoreValuation Measures
Market Cap
661.89M
Enterprise Value
456.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.38
Enterprise Value/Revenue
147.75
Enterprise Value/EBITDA
-16.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.57%
Return on Equity (ttm)
-145.41%
Revenue (ttm)
4.49M
Net Income Avi to Common (ttm)
-147.74M
Diluted EPS (ttm)
-3.43
Balance Sheet and Cash Flow
Total Cash (mrq)
260.99M
Total Debt/Equity (mrq)
37.99%
Levered Free Cash Flow (ttm)
-57.41M